抗抑郁反应与氟伏沙明血药浓度：一项初步研究。

Antidepressant response and fluvoxamine plasma concentrations: a pilot study.

作者信息

Schwarzenbach Florence, Netillard Christian, Demoly Patricia, Bisschop Dorothé, Limat Samuel, Bouquet Serge, Vandel Sylvette, Bel Anne-Marie, Woronoff-Lemsi Marie-Christine

机构信息

Pharmacy, Psychiatric Hospital, F-25150 Novillars, France.

出版信息

Pharm World Sci. 2003 Feb;25(1):27-9. doi: 10.1023/a:1022410306577.

DOI:10.1023/a:1022410306577

PMID:12661474

Abstract

The objective of this pilot study was to examine the relation between fluvoxamine (FVX) plasma concentrations, therapeutic response and side effects during a four-week treatment period. Twenty-two patients who met the DSM-IV criteria for major depression received 100 mg FVX during the first 2 days of treatment and then 150 or 200 mg/day. No clear relationship between plasma concentrations and side effects was detectable. A relationship between plasma concentrations and clinical efficacy was detectable after 21 days but not after 28 days of treatment. These preliminary results indicate that therapeutic drug monitoring might be useful for patients treated with FVX.

摘要

这项初步研究的目的是在为期四周的治疗期间，研究氟伏沙明（FVX）血药浓度、治疗反应和副作用之间的关系。22名符合《精神疾病诊断与统计手册》第四版（DSM-IV）重度抑郁症标准的患者在治疗的前两天接受100毫克FVX，然后每天接受150或200毫克。未发现血药浓度与副作用之间存在明显关系。治疗21天后可检测到血药浓度与临床疗效之间的关系，但治疗28天后未检测到。这些初步结果表明，治疗药物监测可能对接受FVX治疗的患者有用。